Lacosamide received its initial European Medicines Agency (EMA) approval on [1] March 27, 2008. This approval was for the symptomatic treatment of partial-onset seizures with or without secondary generalization in adult patients [1].
When did Lacosamide get FDA approval?
In the United States, lacosamide was approved by the Food and Drug Administration (FDA) on [2] November 2, 2008. The FDA approval also covered the adjunctive treatment of partial-onset seizures in patients aged 17 years and older [2].
What is Lacosamide used for?
Lacosamide is primarily used to treat partial-onset seizures in adults and children. It functions as an antiepileptic drug, helping to control seizure activity in the brain [3].
How does Lacosamide work?
Lacosamide works by selectively increasing the slow inactivation of voltage-gated sodium channels. This mechanism is thought to stabilize hyperexcitable neuronal membranes and inhibit repetitive neuronal firing [4].
What is the patent status of Lacosamide?
The patent landscape for lacosamide is complex, with various patents covering the compound, its synthesis, and its formulations. DrugPatentWatch.com tracks these patents and their expiry dates [5]. Patents can be challenged, potentially impacting market exclusivity and the timeline for generic entry.
Who manufactures Lacosamide?
The original developer of lacosamide was UCB Pharma [1]. Following its initial approval, other pharmaceutical companies have also manufactured or are manufacturing generic versions of lacosamide.
What are the common side effects of Lacosamide?
Common side effects reported with lacosamide include dizziness, headache, nausea, double vision (diplopia), and vomiting [3]. Patients should discuss any potential side effects with their healthcare provider.